Century Therapeutics, Inc. (IPSC): Capital Expenditures
$848.0K
Year ended 2025-12-31
$1.33M
Trailing 12 months to 2026-06-30
-69.7%
3-year compound annual growth
-38.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $848.0K | +450.6% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $154.0K | -98.9% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $13.74M | -55.1% | 2025-03-19, From 2023-01-01 |
| 2022-12-31 | $30.60M | -31.9% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $44.97M | +357.7% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $9.82M | n/a | 2022-03-17, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $848.0K | +450.6% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $3.85M | -44.2% |
| Agenus Inc (AGEN) | 2025-12-31 | $6.0K | -99.0% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $0 | -100.0% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $4.70M | +17.9% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $14.95M | +67.1% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $536.0K | -85.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $3.83M | -22.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $19.04M | -13.7% |
Compare IPSC, IBRX, AGEN, ATRA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗